valosin containing protein
Dernière mise à jour 8 mai 2023
Respecte les directives éditoriales
- TéléchargerTélécharger
- Partager
- Language
- Discussion
- Version audio
- Ajouter aux sources préférées sur Google
La VCP gene provides instructions for making an enzyme called valosin-containing protein. This enzyme is found throughout the body and has a wide variety of functions within cells. It is involved in cell division, joining (fusing) membranes within cells, reassembling cell structures after cells have divided, preventing the self-destruction of cells (apoptosis), and repairing damaged DNA.
Normal function
La VCP gene provides instructions for making an enzyme called valosin-containing protein. This enzyme is found throughout the body and has a wide variety of functions within cells. It is involved in cell division, joining (fusing) membranes within cells, reassembling cell structures after cells have divided, preventing the self-destruction of cells (apoptosis), and repairing damaged DNA.
Valosin-containing protein is part of the ubiquitin-proteasome system, which is the machinery that breaks down (degrades) unneeded proteins within cells. This system provides quality control by disposing of damaged, misshapen, and excess proteins. It also regulates the level of proteins involved in several critical cell activities, such as the timing of cell division and growth. Researchers believe that most of the functions of valosin-containing protein are directly or indirectly related to the ubiquitin-proteasome system.
Conditions referring to this gene or chromosome
Other names
15S Mg(2+)-ATPase p97 subunit
CDC48
IBMPFD
MGC131997
MGC148092
MGC8560
p97
TER ATPase
TERA
TERA_HUMAN
Related patient information and medicines
Patient information leaflet
Lentilles de contact
Place the lens in the (cleaned) lens case and fill with fresh solution (don't... Disinfecting kills bugs (pathogens) on the lens. Depending on how much protéines your eyes deposit on your contacts, you may need to use a product for protein removal. Cleaning removes some protein but it can build up on extended-wear lenses and can make them.
Patient information leaflet
Alimentation saine
You can reduce your intake of trans fats by avoiding or reducing the amount of fried foods, high-fat snacks and ... A 2019 review by the SACN (The Scientific Advisory Committee on Nutrition) determined that reducing your intake of saturated fats lowers your risk of developing coronary heart disease, although there was no evidence that it reduces.
Patient information leaflet
Puis-je prendre Atorvastatine et Mirabegron ensemble ?
This could potentially increase the risk of side effects from the statin, such as muscle aches or pain. Why this happens Mirabegron can slightly interfere with a protein (CYP3A4) and a transporter (P-gp) that the body uses to break down and remove atorvastatin. This means the atorvastatin stays in your system a bit longer than usual. Our Medicines.
Patient information leaflet
Puis-je prendre Warfarine et Aspirine ensemble ?
...spirin together significantly increases your risk of serious bleedingWarfarin interferes with the proteins (clotting factors) needed to form a clot, while aspirin stops blood cells called platelets from sticking together. Disclaimer This information is for general educational purposes only and should not be relied upon as a substitute for.
Patient information leaflet
Syndrome néphrotique
Nephrotic syndrome is a condition where the 'filters' in the kidney become 'leaky' and large amounts of protéines leak from the blood into the urine. If high blood pressure develops then treatmen... A medicine called an inhibiteur de l'enzyme de conversion de l'angiotensine (ECA) ou un angiotensin-II receptor antagonist (AIIRA) - sometimes called an angiotensin.
Patient information leaflet
Glomérulonéphrite
What is glomerulonephritis. Glomérulonéphrite is the name given to a range of conditions that can affect the glomeruli of the kidney. Or it can be chronic. Many cases of glomerulonephritis are thought to be caused by a problem with the immune system, so steroid medicines, or sometimes more powerful me... Angiotensin-converting enzyme (ACE).
Lectures complémentaires et références
- valosin containing protein; MedlinePlus, National Library of Medicine.
- Guinto JB, Ritson GP, Taylor JP, Forman MS. Valosin-containing protein and the pathogenesis of frontotemporal dementia associated with inclusion body myopathy. Acta Neuropathol. 2007 Jul;114(1):55-61. doi: 10.1007/s00401-007-0224-7. Epub 2007 Apr 25.
- Ju JS, Miller SE, Hanson PI, Weihl CC. Impaired protein aggregate handling and clearance underlie the pathogenesis of p97/VCP-associated disease. J Biol Chem. 2008 Oct 31;283(44):30289-99. doi: 10.1074/jbc.M805517200. Epub 2008 Aug 20.
- Korb M, Peck A, Alfano LN, Berger KI, James MK, Ghoshal N, Healzer E, Henchcliffe C, Khan S, Mammen PPA, Patel S, Pfeffer G, Ralston SH, Roy B, Seeley WW, Swenson A, Mozaffar T, Weihl C, Kimonis V; VCP Standards of Care Working Group. Development of a standard of care for patients with valosin-containing protein associated multisystem proteinopathy. Orphanet J Rare Dis. 2022 Jan 29;17(1):23. doi: 10.1186/s13023-022-02172-5.
- Meyer H, Weihl CC. The VCP/p97 system at a glance: connecting cellular function to disease pathogenesis. J Cell Sci. 2014 Sep 15;127(Pt 18):3877-83. doi: 10.1242/jcs.093831. Epub 2014 Aug 21.
- Nalbandian A, Donkervoort S, Dec E, Badadani M, Katheria V, Rana P, Nguyen C, Mukherjee J, Caiozzo V, Martin B, Watts GD, Vesa J, Smith C, Kimonis VE. The multiple faces of valosin-containing protein-associated diseases: inclusion body myopathy with Paget's disease of bone, frontotemporal dementia, and amyotrophic lateral sclerosis. J Mol Neurosci. 2011 Nov;45(3):522-31. doi: 10.1007/s12031-011-9627-y. Epub 2011 Sep 3.
- Song C, Wang Q, Li CC. Characterization of the aggregation-prevention activity of p97/valosin-containing protein. Biochemistry. 2007 Dec 25;46(51):14889-98. doi: 10.1021/bi700499j. Epub 2007 Nov 29.
- Watts GD, Thomasova D, Ramdeen SK, Fulchiero EC, Mehta SG, Drachman DA, Weihl CC, Jamrozik Z, Kwiecinski H, Kaminska A, Kimonis VE. Novel VCP mutations in inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia. Clin Genet. 2007 Nov;72(5):420-6. doi: 10.1111/j.1399-0004.2007.00887.x.
- Watts GD, Wymer J, Kovach MJ, Mehta SG, Mumm S, Darvish D, Pestronk A, Whyte MP, Kimonis VE. Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nat Genet. 2004 Apr;36(4):377-81. doi: 10.1038/ng1332. Epub 2004 Mar 21.
Participez à la conversation
Partagez vos pensées ou expériences avec les autres dans notre communautés de patients.
Demandez, partagez, connectez-vous.
Parcourez les discussions, posez des questions et partagez vos expériences sur des centaines de sujets de santé.
Inscrivez-vous à la newsletter Patient
Votre dose hebdomadaire de conseils de santé clairs et fiables - rédigés pour vous aider à vous sentir informé, confiant et maître de la situation.
En vous abonnant, vous acceptez notre Politique de confidentialité. Vous pouvez vous désabonner à tout moment. Nous ne vendons jamais vos données.